Maryland's Medical Marijuana Industry to be Regulated by Alcohol and Tobacco Commission.

Dec.20.2022

Maryland MMJ industry oversight to be transferred to state's alcohol and tobacco commission starting 2023. Adult-use sales legalized.

Beginning in 2023, the medical marijuana industry in Maryland, United States, will be regulated by the state's alcohol and tobacco commission.

The Marijuana Medical Commission of Maryland (MMCC) has been overseeing the state's medical marijuana industry since sales began in December 2017.

During the midterm elections in November, the situation changed as Maryland voters decided to legalize the sale of marijuana for adult use.

According to a press release from MMCC, the regulation of medical marijuana will transition from the Medical Marijuana Commission to the Alcohol and Tobacco Commission in 2023, as mandated by a law passed by voters.

According to an announcement, Chairperson Tiffany Randolph will step down on December 31st.

In the past five years, commission members and staff have established Maryland as a model for medical marijuana programs and have helped the state prepare for the transition to an expanded medical and adult-use market," said Randolph in a statement.

According to a press release, Dr. C. Obi Onyewu, current Vice-Chair of MMCC, will serve as acting Chair as Maryland launches a recreational marijuana market.

Starting from July 1, 2023, it will be legal for adults aged 21 and above to consume and possess up to 1.5 ounces of marijuana.

The true retail market may not begin until 2024 or 2025.

#E-cigarette Industry #Medical marijuana dispensary #USA

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Shenzhen Tobacco Authority Completes Successful Quality Inspection of E-cigarette Products, All Safety Criteria Met

Shenzhen Tobacco Bureau announces successful quality inspection of e-cigarette products, meeting national standards.

Dec.08 by 2FIRSTS.ai

Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model

The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.

Regulations

Dec.20

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

Wisconsin Lawmakers Revive Bill to Raise Legal Age for Tobacco and Vaping Purchases to 21

Wisconsin Senate Bill 524 (SB 524) has been reintroduced to raise the legal purchasing age for tobacco and electronic nicotine products from 18 to 21, aiming to eliminate the gap between state law and the federal “Tobacco 21” standard. Some retailers in Madison have already voluntarily adopted the 21-year age limit, while the American Lung Association is urging swift legislative action.